Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute Present Research at the American Urological Association (AUA) Meeting

AUA group
Fox Chase Cancer Center and Fox Chase - Temple Urologic Institue physicians at AUA 2025 

PHILADELPHIA (April 28, 2025) — Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute physicians participated in the presentation and discussion of a number of research projects at the American Urological Association meeting, held April 26-29 in Las Vegas.

Panels, posters and abstracts:
Saturday, April 26, 2025

Danly Omil-Lima, MD, Urologic Oncology Fellow at Fox Chase Cancer Center
MP02: “Oncocytic Renal Neoplasms” Developed Distant Metastases: Long-term Follow-up in Two Health Systems 

Robert Uzzo, MD, MBA, FACS, President and CEO at Fox Chase Cancer Center
Case-Based Guidelines Panel Discussion: Management of Small Renal Mass

Luke Shumaker, MD, Robotic Urologic Oncology and Reconstructive Surgery Fellow at Fox Chase Cancer Center
IP03-15: Robot-assisted Transvesical Simple Prostatectomy with Circumferential Mucosal Anastomosis: Long-term Urinary and Sexual Function Outcomes in a 292 Patient Cohort

Jessica Pryor, MD, Urologic Oncology Resident at Fox Chase Cancer Center
IP03-20: Post-procedural urethral strictures after Aquablation®

Daniel D. Eun, MD, Professor of Urology at Fox Chase-Temple Health Urologic Institute
Robotic Ureteral Reimplantation

Robert Uzzo, MD, MBA, FACS, President and CEO at Fox Chase Cancer Center
Controversies in Urology: 3 cm Renal Mass, which is the Best Treatment Alternative

Joshua Cohn, MD, FPMRS, Associate Professor of Urology at Fox Chase-Temple Health Urologic Institute
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)

Arveen Asghar,
MP09-06-Describing the quality-of-life response for patients who experience a complication after radical cystectomy

Danly Omil-Lima, MD, Urologic Oncology Fellow at Fox Chase Cancer Center
MP09: Lagging Adoption of Active Surveillance in Small Renal Masses: A Comparison to Low-Risk Prostate Cancer 

Jay Simhan, MD, FACS, Director of Reconstruction and Prosthetics at Fox Chase Cancer Center
Intraoperative Management of Select Penile Prosthesis Scenarios

Mary Barb, PhD, Professor, Lewis Katz School of Medicine at Temple University
PD09-07: Elevated protein levels of brain-derived neurotrophic factor and reactive oxygen species in the mucosa of lower motor neuron-lesioned dog bladder following somatic-motor nerve transfer

Sunday, April 27, 2025

Daniel D. Eun, MD, Professor of Urology at Fox Chase-Temple Health Urologic Institute    
0251C – Robotic Upper Tract Reconstruction: Principles, Techniques, and Complications

David Y.T. Chen, MD, FACS, Professor of Urology at Fox Chase-Temple Health Urologic Institute
V05: Prostate Oncology/Penile & Testis Oncology/Misc. Oncology II

Francesca Montanaro, MD, Co-Authors from Fox Chase-Temple Urologic Institute: Shivaram Cumarasamy, MD; Michael Lesgart; Robert G Uzzo, MD, MBA; Alexander Kutikov, MD; Randall A Lee MD
MP17-01: Radiological Evaluation of Large Cystic Renal Masses: Bridging the Gap with Pathological Findings

Daniel D. Eun, MD, Professor of Urology at Fox Chase-Temple Health Urologic Institute
Robotics Theater: Reconstruction

Matthew Lee, MD, MBA, Urology Resident at Fox Chase-Temple Urologic Institute
MP20-06: Multi-Institutional Outcomes of Robotic Ureteral Reconstruction for Endometriosis-Induced Strictures

Michael A. Pontari, MD, Professor and Vice Chair of Urology, Fox Chase-Temple Urologic Institute
Case-based Guidelines Panel Discussion: Chronic Pelvic Pain
8:25-9:05 a.m., Venetian Ballroom

Zafardjan Dalimov, MD, Co-Authors from Fox Chase-Temple Urologic Institute: Samuel Ivan, MD; Jay Simhan, MD
IP18-13: A Multi-Institutional Analysis of Rear Tip Extender Use and Inflatable Penile Prosthesis Complications in Patients Undergoing Primary Inflatable Penile Prosthesis Placement: Results from PUMP Collaborative

Samuel Ivan, MD, Reconstructive and Prosthetic Urology Fellow at Fox Chase Cancer Center
IP18-04: Infection Rates with Intraoperative 0.05% Chlorhexidine Gluconate in Hydrophilic Coated Inflatable Penile Prostheses: Initial Results from a Large Multi-Institutional Cohort
IP18-05: Characteristics of Inflatable Penile Prosthesis Infections After Intraoperative 0.05% Chlorhexidine Gluconate: Results from a Large Multi-Institutional Cohort

Matthew Lee, MD, MBA, Urology Resident at Fox Chase-Temple Urologic Institute
PD25-02: Rest and Reveal: Radiographic Changes After Ureteral Rest for Robotic Ureteral Reconstruction

Michael Lesgart, Temple Medical Student
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Joshua Cohn, MD, FPMRS, Associate Professor of Urology at Fox Chase-Temple Urologic Institute
Society for the Study of Male Reproduction (SSMR)

Cassra Clark, MD, Co-Author from Fox Chase-Temple Urologic Institute: Alexander Kutikov, MD
PD28-06: Self-reported peri-operative outcomes of patients undergoing urinary diversion utilizing the ACS Ostomy Home Skills Kit

Matthew Lee, MD, MBA, Urology Resident at Fox Chase-Temple Urologic Institute
V14-06: Shedding New Light On Indocyanine Green During Robotic Ureteral Reconstruction: A Multi-Institutional Collaborative

Daniel D. Eun, MD, Professor of Urology at Fox Chase-Temple Health Urologic Institute
Buccal Mucosa Ureteroscopy: A Decade of Success

Luke Shumaker, MD, Robotic Urologic Oncology and Reconstructive Surgery Fellow at Fox Chase Cancer Center
V14-07: Technical Nuances for Success: Preserving Blood Supply in Obliterated Ureteral Strictures

Daniel D. Eun, MD, Professor of Urology at Fox Chase-Temple Health Urologic Institute
Case Presentations and Panel Discussion

Tamir Sholklapper, MD, MS, Co-Authors from Fox Chase-Temple Urologic Institute: Shivaram Cumarasamy, MD; Andres Correa, MD; Jay Simhan, MD; Alexander Kutikov, MD
PD28-11: Very Low Rate of Parastomal Hernia Using Partially Absorbable Macroporous Mesh for Prophylactic Reinforcement in Ileal Conduit Urinary Diversion: A Collaborative Approach Between Urology and Plastic/Reconstructive Surgery

Michael A. Pontari, MD, Professor and Vice Chair of Urology, Fox Chase-Temple Urologic Institute
MP31: Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia

Gedaliah Ber (Moshe) Meadvin, Temple Medical Student
MP32-07: Exploring the Relationship between prostate MRI adoption and Rate of Negative Prostate Biopsy – Insights from a large quality collaborative

Jay Simhan, MD, FACS, Director of Reconstruction and Prosthetics at Fox Chase Cancer Center
060IC - Advances in Urethral Reconstruction

Tuesday, April 29, 2025

Daniel D. Eun, MD, Professor of Urology at Fox Chase-Temple Health Urologic Institute
Panel Discussion: How Best to Manage a Patient with 1cm Proximal Ureteral Stricture Following Ureteroscopy for an Impacted Stone

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427